Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies in 1H26 – – New Drug Application for rademikibart for ...

Research on adults who take S.S.R.I.s shows they tamp down sexual desire. Why aren’t we studying what that could mean for ...

Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (Nasdaq:LPTX), a company developing novel therapies ...

Q3 2025 Earnings Call Transcript November 10, 2025 AST SpaceMobile, Inc. misses on earnings expectations. Reported EPS is $-0 ...

Explore Harding Loevner's Q3 2025 Global Small Companies report. Learn why momentum markets impacted returns and our ...

BigBear.ai Holdings, Inc. (NYSE: BBAI) , a leader in AI-powered decision intelligence solutions, recently announced financial results for the third quarter of 2025 and issued an investor presentation ...

Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies in 1H26 - - New Drug Application for rademikibart ...

AI drives decision inputs: In 2025, both big pharma and small pharma use advanced predictive modeling, digital twins, and AI-powered analytics throughout R&D and regulatory processes. This reduces ...

Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 - - Reported highly positive 12-week primary endpoint results from Phase 2 ...

Q3 2025 Earnings Call Transcript November 11, 2025 Operator: Good morning, and good evening, ladies and gentlemen. Thank you ...

BPL-003 (mebufotenin benzoate nasal spray) granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for ...

Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (Nasdaq:LPTX), a company developing novel therapies for patients ...